This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB05511/identifier/bindingdb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05511/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05511/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05511/identifier/chemspider/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05511
rdf:type
n3:Drug
n3:description
CF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as an oral drug and has an excellent safety profile. It is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome.
n3:generalReferences
# Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P: The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs. 2007 Oct;16(10):1601-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17922624
n3:group
investigational
n3:indication
Investigated for use/treatment in cancer/tumors (unspecified), eye disorders/infections, psoriasis and psoriatic disorders, and rheumatoid arthritis. Can-Fite BioPharma has reported that by targeting the adenosine A3-receptor, CF101 may also be used to treat Crohn's disease, a serious gastrointestinal disorder.
owl:sameAs
n6:DB05511
dcterms:title
CF-101
adms:identifier
n8:50118812 n9:123683 n10:110259 n11:DB05511
n3:mechanismOfAction
CF 101 is an A(3)AR agonist. A(3)AR is highly expressed in inflammatory cells and overexpressed in peripheral blood mononuclear cells, reflecting its role in the remote inflammatory process. In normal tissues, there is low adenoside A3 receptor expression. A(3)AR activation with a specific agonist deregulates the NF-kappaB signaling pathway in inflammatory cells and initiates immunomodulatory effects.
n3:synonym
IB-MECA
n3:IUPAC-Name
n4:271B458F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4595-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4594-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4591-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4592-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4593-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B458D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B458E-363D-11E5-9242-09173F13E4C5 n4:271B458B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B458C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B459B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B459C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4596-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4597-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4599-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4598-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B459A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B45A1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B45A3-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B45A4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B45A0-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B459F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B45A2-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4590-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B459D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B459E-363D-11E5-9242-09173F13E4C5